Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01183-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863263623905280 |
|---|---|
| author | Rossana Di Staso Beatrice Casadei Frederick L. Locke Michael Jain Timothy J. Voorhees Adam S. Kittai Mariana Bastos-Oreiro Antonio Gutiérrez Alejandro Martin Garcia-Sancho Maria Jose Terol Monica Mead Michael J. Maranzano Gloria Iacoboni Pere Barba Mi Kwon Rebeca Bailen Juan Luis Reguera-Ortega Agrima Mian Brian Hill Emmanuel Bachy Franck Morschhauser Roch Houot Catherine Thieblemont Steven Le Gouill Riccardo Masetti Davide Gori Alessandro Broccoli Pier Luigi Zinzani Lisa Argnani |
| author_facet | Rossana Di Staso Beatrice Casadei Frederick L. Locke Michael Jain Timothy J. Voorhees Adam S. Kittai Mariana Bastos-Oreiro Antonio Gutiérrez Alejandro Martin Garcia-Sancho Maria Jose Terol Monica Mead Michael J. Maranzano Gloria Iacoboni Pere Barba Mi Kwon Rebeca Bailen Juan Luis Reguera-Ortega Agrima Mian Brian Hill Emmanuel Bachy Franck Morschhauser Roch Houot Catherine Thieblemont Steven Le Gouill Riccardo Masetti Davide Gori Alessandro Broccoli Pier Luigi Zinzani Lisa Argnani |
| author_sort | Rossana Di Staso |
| collection | DOAJ |
| format | Article |
| id | doaj-art-43e03c8577e3401699a0eac8f43eb23f |
| institution | Kabale University |
| issn | 2044-5385 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-43e03c8577e3401699a0eac8f43eb23f2025-02-09T12:13:08ZengNature Publishing GroupBlood Cancer Journal2044-53852024-11-011411510.1038/s41408-024-01183-8Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphomaRossana Di Staso0Beatrice Casadei1Frederick L. Locke2Michael Jain3Timothy J. Voorhees4Adam S. Kittai5Mariana Bastos-Oreiro6Antonio Gutiérrez7Alejandro Martin Garcia-Sancho8Maria Jose Terol9Monica Mead10Michael J. Maranzano11Gloria Iacoboni12Pere Barba13Mi Kwon14Rebeca Bailen15Juan Luis Reguera-Ortega16Agrima Mian17Brian Hill18Emmanuel Bachy19Franck Morschhauser20Roch Houot21Catherine Thieblemont22Steven Le Gouill23Riccardo Masetti24Davide Gori25Alessandro Broccoli26Pier Luigi Zinzani27Lisa Argnani28Department of Medical and Surgical Sciences, University of BolognaIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”Moffitt Cancer CenterMoffitt Cancer CenterDivision of Hematology, The Ohio State UniversityDivision of Hematology, The Ohio State UniversityInstituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio MarañónUnit of Lymphoma. Department of Hematology. Son Espases University Hospital (IdISBa)Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain; University of SalamancaServicio de Hematología y Oncología Médica, Hospital Clinico Universitario de ValenciaDepartment of Medicine/Division of Hematology and Oncology, UCLA Medical CenterDepartment of Medicine/Division of Hematology and Oncology, UCLA Medical CenterDepartment of Hematology, University Hospital Vall d’HebronDepartment of Hematology, University Hospital Vall d’HebronDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de MadridDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de MadridHospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) / CSIC, Universidad de SevillaDepartment of Hematology and Medical Oncology Taussig Cancer Institute Cleveland ClinicDepartment of Hematology and Medical Oncology Taussig Cancer Institute Cleveland ClinicCentre Hospitalier Lyon-SudHematology Department, Centre Hospitalier Régional Universitaire de LilleDepartment of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of RennesHematology Department, Hôpital Saint-LouisHematology Department, Institut CurieDepartment of Medical and Surgical Sciences, University of BolognaDepartment of Biomedical and Neuromotor Sciences, University of BolognaDepartment of Medical and Surgical Sciences, University of BolognaDepartment of Medical and Surgical Sciences, University of BolognaDepartment of Medical and Surgical Sciences, University of Bolognahttps://doi.org/10.1038/s41408-024-01183-8 |
| spellingShingle | Rossana Di Staso Beatrice Casadei Frederick L. Locke Michael Jain Timothy J. Voorhees Adam S. Kittai Mariana Bastos-Oreiro Antonio Gutiérrez Alejandro Martin Garcia-Sancho Maria Jose Terol Monica Mead Michael J. Maranzano Gloria Iacoboni Pere Barba Mi Kwon Rebeca Bailen Juan Luis Reguera-Ortega Agrima Mian Brian Hill Emmanuel Bachy Franck Morschhauser Roch Houot Catherine Thieblemont Steven Le Gouill Riccardo Masetti Davide Gori Alessandro Broccoli Pier Luigi Zinzani Lisa Argnani Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma Blood Cancer Journal |
| title | Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma |
| title_full | Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma |
| title_fullStr | Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma |
| title_full_unstemmed | Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma |
| title_short | Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma |
| title_sort | is car t a drug or a therapeutic pathway intention to treat versus per protocol analysis of real world studies of car t cell therapy in relapsed refractory diffuse large b cell lymphoma |
| url | https://doi.org/10.1038/s41408-024-01183-8 |
| work_keys_str_mv | AT rossanadistaso iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT beatricecasadei iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT frederickllocke iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT michaeljain iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT timothyjvoorhees iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT adamskittai iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT marianabastosoreiro iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT antoniogutierrez iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT alejandromartingarciasancho iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT mariajoseterol iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT monicamead iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT michaeljmaranzano iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT gloriaiacoboni iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT perebarba iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT mikwon iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT rebecabailen iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT juanluisregueraortega iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT agrimamian iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT brianhill iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT emmanuelbachy iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT franckmorschhauser iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT rochhouot iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT catherinethieblemont iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT stevenlegouill iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT riccardomasetti iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT davidegori iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT alessandrobroccoli iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT pierluigizinzani iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma AT lisaargnani iscartadrugoratherapeuticpathwayintentiontotreatversusperprotocolanalysisofrealworldstudiesofcartcelltherapyinrelapsedrefractorydiffuselargebcelllymphoma |